15P STELLAR-001: A phase I study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors

Avdoralimab (IPH5401) is a monoclonal antibody that inhibits the binding of the complement factor C5a to the receptor C5aR1. Preclinical analysis revealed that inhibition of C5a/C5aR1 axis limited myeloid derived suppressor cells (MDSCs) and increased CD8 T-cell tumor infiltration, promoting tumor reduction and limiting metastatic potential. Furthermore, the combined use of C5a/C5aR1 inhibition and anti-PD(L)1 therapy (IO) was shown to be superior to each modality alone in terms of reducing tumor volume and improving survival in several preclinical murine models.